JSLL Jeena Sikho Q4 FY26 results (Jan–Mar 2026) and concall
Jeena Sikho delivered robust financial performance in FY26 with significant growth in revenue, EBITDA, and PAT, driven by increased patient volumes and improved operational efficiency. Despite Q4 being impacted by one-time expenses and geopolitical events, the company remains focused on its preventive Ayurveda model, operational expansion, and ambitious long-term growth targets for bed capacity and profitability.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 55.4%, net profit up 80.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 114 | 116 | 139 | 174 | 190 +67% | 222 +91% | 216 +55% |
| EBITDA | 40 | 30 | 46 | 79 | 92 +130% | 101 +237% | 78 +70% |
| Net profit | 27 | 13 | 25 | 51 | 59 +119% | 67 +415% | 45 +80% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
